<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511029</url>
  </required_header>
  <id_info>
    <org_study_id>223HV102</org_study_id>
    <nct_id>NCT01511029</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)</brief_title>
  <official_title>A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to
      healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, single-center, blinded (with respect to dexpramipexole administration),
      randomized, placebo- and active-controlled, 4-period crossover study in approximately 68
      healthy volunteers. This thorough QT/QTc study will be conducted to formally evaluate the
      effect of dexpramipexole on QT prolongation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether a single dose of dexpramipexole prolongs the QTC interval as measured by frequent ECG measurements (using Holter monitoring) of individually corrected QT intervals (QTcI)</measure>
    <time_frame>change from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of dexpramipexole</measure>
    <time_frame>pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 23 hours after dosing on Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG measurements</measure>
    <time_frame>baseline and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of dexpramipexole</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 23 hours after dosing on Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of dexpramipexole</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 23 hours after dosing on Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dexpramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexpramipexole (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole</intervention_name>
    <description>300 mg - Oral Tablets</description>
    <arm_group_label>Dexpramipexole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole</intervention_name>
    <description>600 mg Oral Tablets</description>
    <arm_group_label>Dexpramipexole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole Placebo</intervention_name>
    <description>Placebo - Oral Tablet</description>
    <arm_group_label>Dexpramipexole (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg - Oral Tablet</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 60 years old inclusive on Day 1.

          -  Subjects who, in the opinion of the Investigator, are healthy as determined by pre
             study medical history, physical examination, and 12 lead ECG.

          -  Male subjects and female subjects of childbearing potential must practice effective
             contraception (per protocol specifications).

          -  Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg
             and a diastolic blood pressure of 50 to 90 mmHg.

        Exclusion Criteria:

          -  History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long
             QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc
             interval), in the opinion of the Investigator.

          -  A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval
             &gt;450 ms before study treatment administration.

          -  Clinically important abnormalities in resting ECG that may interfere with the
             interpretation of QTc interval changes at screening, check-in, or pre-dose on Day -1
             of the first treatment period.

          -  Other medically significant illness.

          -  Clinically significant abnormal laboratory values.

          -  Pregnant women or women breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

